Introduction {#sec1_1}
============

The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, as a first- or second-line therapy in EGFR-positive non-small cell lung cancer has increased progression-free survival \[[@B1]\]. The cutaneous side effects of this treatment include papulopustular eruption, xerosis, photosensitivity, alopecia, paronychia, onycholysis, and brittle nails \[[@B2]\]. About 80% of patients treated with EGFR inhibitors develop a papulopustular eruption and up to 32% of these are severe enough to be treated with minocycline or doxycycline \[[@B2]\]. Inadequate control of cutaneous side effects leads to impaired quality of life, decreased compliance, and dose reduction \[[@B3]\]. In addition, the tetracyclines used to treat these side effects have their own toxicities. In dermatology literature, minocycline for the treatment of acne, rosacea, and blistering diseases is well known to cause blue-black pigmentation of the skin, eyes, bones, existing scars, and teeth \[[@B4]\]. However, in oncology literature, there are rare reports of minocycline hyperpigmentation when used to treat EGFR inhibitor-induced papulopustular eruptions.

Case Report {#sec1_2}
===========

An 87-year-old man with EGFR-positive non-small cell lung adenocarcinoma stage IV (T1aN3M1b) was started on erlotinib 150 mg daily in October 2013. He presented with inflammatory follicular-based papules and pustules over the face after 3 weeks of treatment. Two months later, the eruption involved greater than 50% of his body and he self-discontinued erlotinib. Subsequently, he was treated with minocycline 100 mg twice daily and was restarted on a decreased dose of erlotinib (50 mg daily). After 8 months of minocycline, he developed new blue-gray patches over his shins that eventually spread to thighs, arms, hands, existing scars, sclera, and teeth (Fig. [1](#f1){ref-type="fig"}, Fig. [2](#f2){ref-type="fig"}). For 30 weeks, the discoloration was attributed to erlotinib, although hyperpigmentation is not a common side effect of this therapy. Upon consultation to dermatology, a skin biopsy confirmed dermal pigmentation consistent with minocycline (Fig. [3](#f3){ref-type="fig"}). His medication was changed to doxycycline and the pigmentation was treated with laser therapy, eventually fading.

Discussion {#sec1_3}
==========

Optimization and treatment of skin-related side effects remains paramount for patient adherence to EGFR inhibitor therapy to prevent dose reduction or discontinuation \[[@B3]\]. However, in current oncology literature, there is little distinction between which tetracycline is favored in the treatment of papulopustular eruptions \[[@B2]\]. We present this case to illustrate a common side effect of prolonged minocycline use that is not well reported in oncology literature.

Pigmentation most commonly occurs on shins, ankles, hands, or forearms, but may involve eyes, bones, existing scars, mucosa, and teeth \[[@B5]\]. Minocycline pigmentation occurs in a dose-dependent fashion, with longer use increasing the risk \[[@B4]\]. Biopsy confirmed this diagnosis with both iron and melanin deposition in macrophages (Fig. [3](#f3){ref-type="fig"}) \[[@B4]\]. Once recognized, discontinuation of therapy results in eventual fading of pigmentation over months to years. To hasten resolution, Q-switch laser is an effective treatment option \[[@B5]\].

With targeted therapies, progression-free survival in non-small cell lung cancer is extending, leading to greater use of minocycline and greater opportunity for such hyperpigmentation. To protect patient compliance to EGFR inhibitors, we recommend greater consideration of the risks and benefits of each tetracycline class, in combination with patient characteristics, when treating erlotinib-based papulopustular eruption.
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![**a** Muddy dark blue to black pigmentation on the dorsal hands. **b** Black to blue patches on the anterior shins, ankles, and dorsal feet.](cro-0010-0156-g01){#f1}

![**a** Blue-gray discoloration of the inferior teeth most notably of the right lateral incisor. **b** A gray discoloration of the medial sclera.](cro-0010-0156-g02){#f2}

![**a** Fontana-Masson stain highlighting dermal melanophages engulfing melanin. **b** Prussian Blue stain showing iron deposition. The combination of dermal pigmentation staining positive for both melanin and iron deposition is consistent with minocycline deposition. Original magnification ×400 (**a** and **b**).](cro-0010-0156-g03){#f3}
